Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
about
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Effect of grapefruit juice on the bioactivation of prasugrelP2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Prasugrel: a critical comparison with clopidogrel.What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.InforMatrix: ADP antagonists in acute coronary syndromes.Prasugrel is effective and safe for neurointerventional procedures.Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Cangrelor for treatment during percutaneous coronary intervention.Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
P2860
Q33569289-E13EBCE4-4C1C-4D13-BB10-8E03E8EBF33EQ34147112-4A770B8A-B214-45A1-96EE-696C955752E2Q35373683-3D6A9729-D227-4F43-88B9-3B3DAAD3F2A0Q35846138-3C907F92-7B65-49A0-8148-85C6A2AD1E6FQ37562606-B8E3F226-8060-47A8-930F-F1A1685AC017Q37629641-0E8A50E4-970A-4E22-9E17-A907E0A4E86CQ37641320-228A183C-58BE-4E8D-8B14-DFB9FF362349Q37704842-7A62C888-036A-4B50-ABA7-30FF0498FEA3Q37973397-4EC23372-C424-4782-8977-561C9AD6AE62Q38012439-886F7715-10A5-447C-9C7E-31D4D74B6232Q38128171-D0D150CB-425C-4093-A174-AB527370896FQ39204251-0EAFBEE8-0004-44EB-A7EE-08347D6D1A28Q42646492-68D8B1A6-BA7B-4644-8BF0-5EC996E3FE7EQ43288118-8424EC11-4D8A-44B8-9426-686DCE685D1A
P2860
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@en
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@nl
type
label
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@en
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@nl
prefLabel
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@en
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@nl
P2093
P2860
P356
P1476
Greater inhibition of platelet ...... ogrel: an integrated analysis.
@en
P2093
Christopher D Payne
Govinda J Weerakkody
Hideo Naganuma
John T Brandt
Joseph A Jakubowski
Kenneth J Winters
P2860
P304
P356
10.1177/1074248407304731
P577
2007-09-01T00:00:00Z